Suchergebnisse - "Grova, Mauro"

PubPharm (33)

1

Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients

enthalten in: Minerva gastroenterology | 2024

von Ingrasciotta, Y. | Grova, M. | Crispino, F. | +6

2

Current Approaches for Monitoring of Patients with Inflammatory Bowel Diseases : A Narrative Review

enthalten in: Journal of clinical medicine | 2024

von Vitello, A. | Maida, M. | Shahini, E. | +6

3

Safety and effectiveness of tofacitinib in ulcerative colitis : Data from TOFA-UC, a SN-IBD study

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2024

von Macaluso, F. | D'Antonio, E. | Fries, W. | +17

4

Role of ustekinumab in treatment of ulcerative colitis : a narrative review

enthalten in: Immunotherapy | 2023

von Grova, M. | Vitello, A. | Mannino, M. | +4

5

Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease

enthalten in: Journal of gastroenterology and hepatology | 2023

von Macaluso, F. | Grova, M. | Mocciaro, F. | +21

6

Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

enthalten in: JHEP reports : innovation in hepatology | 2023

von Reggidori, N. | Bucci, L. | Santi, V. | +91

7

Sarcopenia is a negative predictive factor for endoscopic remission in patients with Crohn's disease treated with biologics

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2023

von Grova, M. | Crispino, F. | Maida, M. | +6

CommentOn: Clin Nutr. 2021 Jun;40(6):4360-4365. - PMID 33516603

8

Exit strategies in inflammatory bowel disease : Looking beyond anti-tumor necrosis factors

enthalten in: World journal of clinical cases | 2023

von Crispino, F. | Michielan, A. | Grova, M. | +4

9

The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2023

von Macaluso, F. | Grova, M. | Saladino, M. | +11

10

Switching from SB2 to PF-06438179/GP1111 and back in inflammatory bowel disease : "The Superswitchers"

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2023

von Macaluso, F. | Casà, A. | Renna, S. | +3